Antimicrobial Resistance and the Test Target Treat Initiative
Antimicrobial resistance is a huge global health issue and contributes significantly to patient mortality and rising healthcare costs across the world. There is a clear need to quickly and accurately identify the nature of a pathogen in order to define the most appropriate treatment strategy with the optimal clinical result.
The Test Target Treat™ initiative from Abbott empowers you to make targeted treatment decisions sooner with rapid diagnostics, reducing inappropriate antimicrobial use and the spread of resistance. We hope to create a shift in treatment trends, moving away from the broad over-prescription of antibiotics, which spawned the growing prevalence of serious healthcare-associated infections like MRSA, towards more targeted therapy.
Content produced by the Alliance for the Prudent Use of Antibiotics (APUA) through an unrestricted educational grant from Abbott Inc.
The Resistance Crisis
Antibiotics are a precious component of the healthcare workers' armamentarium, but they have become a threatened medical resource. The prevalence of antibiotic resistant infections is growing faster than new antibiotics are being developed. For these reasons, each prescription decision impacts the effectiveness of antibiotics for all patients.
APUA's aim is to foster prudent use of antimicrobials by minimizing unnecessary use, targeting therapy to the organism, and reserving broad-spectrum agents for the most urgent needs. This review provides an historical perspective on the antibiotic resistance problem and the unique challenges that it presents to healthcare practitioners, and describes the multifaceted approaches of antimicrobial stewardship that are urgently needed to help preserve these critical resources for generations to come.
Stuart B. Levy, MD 2014